Eli Lilly and Co. offered an outlook for this year that fell below analysts’ expectations, while the pharmaceutical company unveiled a growth strategy reliant on treatments for diabetes and cancer patients, as well as for animals.
from WSJ.com: US Business http://ift.tt/1FmJ12b
via IFTTT
from WSJ.com: US Business http://ift.tt/1FmJ12b
via IFTTT
No comments:
Post a Comment